gmp
gmp

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Budesonide

            Therapeutic Area: Nephrology Product Name: Nefecon

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 08, 2020

            Details:

            Following IND approval by the NMPA in December of 2019 and subsequent approval by Human Genetic Resources Administration of China (HGRAC), the first patient in China has now been randomized in the Phase 3 NefIgArd trial.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Budesonide

            Therapeutic Area: Nephrology Product Name: Nefecon

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Jefferies LLC

            Deal Size: $90.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 05, 2020

            Details:

            Calliditas intends to use the net proceeds for the purposes of funding of its ongoing Phase 3 clinical trial and related trials of Nefecon, pre-commercialization and, if approved, commercialization activities for Nefecon and development of additional product candidates.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Budesonide

            Therapeutic Area: Nephrology Product Name: Nefecon

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $75.0 million Upfront Cash: Undisclosed

            Deal Type: Public Offering May 14, 2020

            Details:

            The net proceeds will be used to advance clinical and commercial developments of Calliditas's lead drug, Nefecon, an oral formulation of the corticosteroid budesonide.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Budesonide

            Therapeutic Area: Nephrology Product Name: Nefecon

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            Details:

            Calliditas does not anticipate a significant impact of the Covid-19 pandemic on the ongoing clinical activities related to NefIgArd, the company's pivotal Phase 3 IgA nephropathy trial.